Sword Health CEO Virgílio (“V”) Bento on Vital Signs
Sword's New AI Solution and Decisions That Shaped the Company
Vital Signs
Health tech company, sub-sector and trend breakdowns
Dormant Last read · last published · next check
Read 1 day ago and current, but nothing has been published for 2 years.
Latest posts
Investing in Abridge
We’re thrilled to announce that Redpoint is co-leading Abridge’s $150M Series C.
Vital Signs Highlights
And a New Season Preview
Mark Cuban on Disrupting PBMs, Staying Curious and Using AI to Avoid NBA Fines
On our latest Vital Signs episode, we talked about problems in pharmacy with Mark Cuban, founder of The Mark Cuban Cost Plus Drug Company.
The Future of AI In Medical Diagnosis: In Conversation With PathAI CEO Dr. Andy Beck
For our second crossover episode between Vital Signs and Unsupervised Learning we explored the impact of AI on pathology with PathAI Co-Founder and CEO Dr.
How Insitro Is Using AI to Create Better Medicines: In Conversation With Daphne Koller
On our first crossover episode between Unsupervised Learning and Vital Signs, we dove deep into the world of using AI in drug development with Insitro CEO Daphne Koller.
Optum's Evolution and Lessons from Obamacare and COVID: In Conversation with Andy Slavitt
On the latest Vital Signs, Nikhil and I chatted with Andy Slavitt, former Optum EVP, head of CMS, COVID advisor and healthcare.gov saver.
How to Sell to Employers and The Future of Mental Healthcare: In Conversation with Naomi Allen
On the latest Vital Signs, Nikhil and I chatted with Naomi Allen, CEO and founder of Brightline, a child and teen focused mental health company that’s raised >$100M from investors like KKR, Google Ventures, Optum and Oak HC/FT.
Building a Platform Biotech and The Future of R&D: In Conversation With Chris Gibson
I sat down with Chris Gibson, co-founder and CEO of Recursion, for part two of a series following up on a few pieces I wrote on pharma software and data including Real World Evidence and R&D tools. Chris and Recursion are at the forefront of using AI for drug discovery. We discussed how Recursion predicted drugs that would be effective for COVID, his take on different techbio business models, and…
The Evolution and Future of Healthcare Data and Building a Vertical SaaS Platform: In Conversation With Dr. Arif Nathoo
I’m kicking off a Vital Signs series following up on a few pieces I wrote on pharma software and data including Real World Evidence and R&D tools. I can’t think of a better person to start things with than Dr. Arif Nathoo, co-founder and CEO of Komodo Health, a fascinating healthcare data company most recently valued at